BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33858788)

  • 1. The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
    Stokkel LE; Stokkel MPM; Donswijk ML; Lahaye MJ; Bekers EM; van Rhijn BWG; Mertens LS
    Clin Genitourin Cancer; 2021 Oct; 19(5):373-380. PubMed ID: 33858788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of
    Das JP; Vargas HA; Ghafoor S; Goh AC; Ulaner GA
    J Nucl Med; 2021 May; 62(5):643-647. PubMed ID: 32948680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging
    Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
    Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
    Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
    BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Value of
    Voskuilen CS; Schweitzer D; Jensen JB; Nielsen AM; Joniau S; Muilwijk T; Necchi A; Azizi M; Spiess PE; Briganti A; Bandini M; Goffin K; Bouchelouche K; van Werkhoven E; Shariat SF; Xylinas E; Azawi NH; Ku JH; Foerster B; van Rhijn BWG; Vegt E; Hendricksen K
    Eur Urol Oncol; 2020 Feb; 3(1):73-79. PubMed ID: 31591037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer.
    Jakobsen JK; Frahm Nielsen T; Ipsen P; Albrecht-Beste E; Cardoso Costa J; Alslev L; Predbjørn Krarup K; Grønkaer Toft B; Høyer S; Bouchelouche K; Bjerggaard Jensen J
    BJU Int; 2021 Feb; 127(2):254-262. PubMed ID: 33448605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.
    Einerhand SMH; van Gennep EJ; Mertens LS; Hendricksen K; Donswijk ML; van der Poel HG; van Rhijn BWG
    Curr Opin Urol; 2020 Sep; 30(5):654-664. PubMed ID: 32701719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
    Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
    Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
    Richters A; van Ginkel N; Meijer RP; Wondergem M; Schoots I; Vis AN; Kiemeney LALM; van Rhijn BWG; Witjes JA; Aben KKH; Mertens LS
    BJU Int; 2023 Oct; 132(4):420-427. PubMed ID: 37246479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma.
    Ottenhof SR; Djajadiningrat RS; Versleijen MWJ; Donswijk ML; van der Noort V; Brouwer OR; Graafland NM; Vegt E; Horenblas S
    Eur Urol Focus; 2022 Jan; 8(1):98-104. PubMed ID: 33685842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
    Shahait M; Abu-Hijlih R; Farkouh A; Obeidat S; Salah S; Abdlkadir AS; Al-Ibraheem A
    J Egypt Natl Canc Inst; 2023 Jul; 35(1):21. PubMed ID: 37455263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added Clinical Value of
    van Ginkel N; van Gennep EJ; Oosterbaan L; Greidanus J; Boellaard TN; Wondergem M; Vis AN; de Reijke TM; van Rhijn BWG; Mertens LS
    Clin Genitourin Cancer; 2023 Jun; 21(3):342-348. PubMed ID: 36918302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.